New to Verisante? Here are a couple links to help you get started:
- the Cancer Research paper summary for the Aura's clinical study https://ens.ewi.tudelft.nl/Education/courses/et4248/Papers/Lui12.pdf
-description of the science behind UBC / BCCA Raman study: watch this:
This video clearly explains VERISANTE TECHNOLOGY's aquired UBC/BCCA science behind both this AURA & CORE Product lines -the middle of the video highlights the CORE for lung cancer and colon cancer and eventual cervical cancer detection.
.
Dr. Haishan Zeng at the end of the video states that he is quite confident that NIR RS gives you the same results as pathology except this technology is non-invasive, not requiring the lesion / mole site to be cut out and biopsied. This device is not actually meant to replace the gold standard of excised biopsy but quite bold statements from the lead Scientist of this amazing device.
.
The fact that SPIE is behind this video that is prominently on display for the scientific community is a giant vote of confidence for UBC's work and Verisante's eventual commercialization.
.
Just with the AURA scanning for all occuring skin cancers - already Verisante's Aura market is 25 TIMES larger then Melafind's melanoma only device. Can't wait for more info on the CORE studies.
On this topic: What things can we look forward to hearing in 2013? Here's a quick summary of my wish list:
- Australian distribution deal
- Starfish Medical is capable of manufacturing as many as forty units a month (AURA) what is the current inventory? What is VRS's Richmond manufacturing capabilities?
- Verisante is expected to keep tight inventory controls possibly even have a waiting list for commercial units rather then keeping surplus inventory on hand quarter to quarter -more confirmation & detail on this
- Aura pre-orders or early sales confirmations
- Aura devices placed in strategic centres with key opinion leaders in the field of skin cancer. Data to be collected to add to FDA efficacy. These KOL's will help with regional promo efforts.
- Brazil & Mexican approval for the Aura in 2013
- Confirmation of VRS's business plan for the Aura e.g. selling prices, rev projections, # of revenue streams, etc. (by approved market/country) despite what people think, this has not yet been set in stone by the company
- IDE (investigative device exemption) approval by the FDA to allow working Aura's to be placed in busy american skin care clinics/centres for rapid data acquisition to support final PMA application
- Announced FDA PMA action items and expected timelines (Emergo Group = VRS consultants on this process – we're watching Emergo, you better be worth the big bucks!) Will VRS have to fund another study for the FDA approval?
- Unexpected awards and accolades e.g. Prism, Edison
- Equity analyst coverage initiation
- An update from Clarion on their website and other social media and mainstream media venues
- Updated Verisante website – possibly a stand-alone Verisante Aura web presence
- CORE UPDATES:
-
- clinical study for lung cancer detection,
- pilot study for colon cancer,
- timelines for cervical cancer development,
- core description for lung cancer –as stand-alone and combined with Clear-Vu Elite
- will the Core have disposable fibre optic probe attachment (recurring revenue stream)?
- Health Canada approval?
- Multi-spectral Imaging product advancement
- Move to the big BOARDS but only after proven sales helps chart global demand and sends the company market cap inline with ZACKS projections.
Did I miss any?
Just my personal thoughts and idea's - do your own DD.
Good luck!